| HOME >> BIOLOGY >> TECHNOLOGY |
MENLO PARK, Calif., Nov. 27 /PRNewswire/ -- Corium International, Inc., a privately-held transdermal drug delivery company, today announced the appointment of Phyllis Gardner, M.D. and Daniel G. Welch to the Board of Directors. Dr. Gardner, an adjunct partner at Essex Woodlands Health Ventures, is a Professor of Medicine at Stanford University and widely published in the fields of cell biology and pharmacology. In addition to her academic work, Dr. Gardner has been active in the biotechnology and pharmaceutical industries. In 1996, she took a leave of absence from Stanford and joined ALZA Corporation as a Principal Scientist, Vice President of Research, and Head of the ALZA Technology Institute. Dr. Gardner is the co-founder of Genomics Collaborative, Inc. (now a division of Bioserve), SKOLAR MD (acquired by Wolters Klure) and APEX DX, LLC. She currently serves on the boards of Ventaira Pharmaceuticals, UMD, Inc., and Revance, Inc., and she is on the Scientific Advisory Board of Aradigm Corp. Dr. Gardner received her M.D. from Harvard Medical School, and received postgraduate training at Massachusetts General Hospital, Stanford School of Medicine, Columbia University and University College London.
Daniel G. Welch has served as Chief Executive Officer and President of
InterMune since September 2003. Prior to InterMune, Mr. Welch was Chairman
and CEO of Triangle Pharmaceuticals, a biopharmaceutical company, which was
acquired by Gilead. From 2000 to 2002, he was President of
Biopharmaceuticals at Elan Corporation where he was responsible for U.S.
commercial operations, the international subsidiaries, the R&D function and
the diagnostics businesses. Mr. Welch served in several senior management
roles at Sanofi-Aventis during the years 1987 to 2000, including Vice
President of Worldwide Marketing and COO of the U.S. business. Prior to
joining Sanofi-Aventis, Mr. Welch was with American Critical Care, a
division of American Hospital Supply. Mr. Welch is a m
'/>"/>
| SOURCE Corium International, Inc. Copyright©2007 PR Newswire. All rights reserved |
Related biology technology :
1. Corium International, Inc., Announces $40 Million Financing led by Essex Woodlands Health Ventures
2. JPMorgans Principal Investment Management Group to Invest in Chindex International, Inc.
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
5. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
6. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
7. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
8. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |